bluuebunny/crossref_metadata_2025_split huggingface dataset:
Exploring concussion awareness in hockey with a First Nations community in Canada
Authors: Hunt Cindy , Michalak Alicja , Lefkimmiatis Chrissy , Johnston Elaine , Macumber Leila , Jocko Tony , Ouchterlony Donna 
Published: April 2018

AbstractObjectiveThe purpose of this pilot study was twofold: (1) to begin to understand concussion in youth hockey in a First Nations community in Canada and (2) to determine the impact of a novel concussion education workshop.DesignA one‐group quasiexperimental time series study was undertaken.SampleA total of 41 participants consented, with 71% (n = 29) completing data collection at all three study time points.Measurement and InterventionsTwo nurses one from the First Nations community and one from the tertiary care center collaborated to develop and deliver the intervention on concussion specifically general, hockey and symptom knowledge. The primary outcome was Total Knowledge Score (TKS), whereby correct responses to a self‐reported questionnaire were summed and then converted to a percentage.ResultsThe TKS were similar across study time points; preworkshop 71.7%, postworkshop 71.8%, and 6‐month follow‐up 72%.ConclusionsNurses worked collaboratively with cultural experts from a First Nations community to integrate Indigenous ways of knowing into concussion awareness and safety for First Nations youth playing hockey.
Sequential systematic anti‐mold prophylaxis with micafungin and voriconazole results in very low incidence of invasive mold infections in patients undergoing allogeneic hematopoietic stem cell transplantation
Authors: Rosillo Claudia , Avila Ana Maria , Huang Yao‐Ting , Devlin Sean , Cho Christina , Montoro Juan , Maloy Molly A. , Papanicolaou Genovefa A. , Barba Pere , Perales Miguel‐Angel 
Published: April 2018

AbstractRecipients of allogeneic hematopoietic stem cell transplantation (allo‐HSCT) are at high risk for invasive mold infections (IMI). The goal of the study is to describe the incidence and outcome of IMI in patients after allo‐HSCT in a large cohort of patients receiving anti‐mold prophylaxis. We conducted a retrospective review of 988 consecutive adults who underwent allo‐HSCT in our center from 2008 through 2014. Standard prophylaxis consisted of micafungin 150 mg IV daily from admission to day +7 ± 3 followed by voriconazole until day +75 to +100. Cases meeting criteria for proven or probable IMI according to EORTC‐MSG criteria were included. Median age at HSCT was 54 years. The most common diagnoses were acute myeloid leukemia (n = 351, 36%) and lymphoid malignancies (n = 248, 25%). Matched related or unrelated donors (URD) were used in 686 (69%) patients, mismatched URD in 142 (14%) and cord blood units in 154 (16%). Twenty‐one patients were diagnosed with IMI after allo‐HSCT, 19 probable and 2 proven, and one patient was diagnosed postmortem. Microbiological diagnosis was established in 9 cases, 5 of them being Aspergillus. One‐year cumulative incidence (CI) of IMI was 1.6% (95% CI 0.9‐2.5) while 12‐week overall survival after IMI was 39% (95% CI 24‐65) Analyzed by disease, there was a trend for a higher 1‐year CI of IMI in patients with ALL (5% [95% CI 1.6‐11.4]) when compared with AML (1.4%), MDS (1.5%) and lymphoma (1.2%), P = .06. The 1‐year CI of IMI after transplantation is low in patients receiving anti‐mold prophylaxis with micafungin bridged to voriconazole, although these infections are associated with a higher risk of mortality.
Graft loss attributed to possible transfusion‐transmitted ehrlichiosis following cord blood stem cell transplant
Authors: Mah Allison , Viola George M. , Ariza Heredia Ella , Rezvani Katayoun , Kebriaei Partow , Bhatti Micah M. , Han Xin , Shpall Elizabeth J. , Mulanovich Victor E. 
Published: April 2018

AbstractWe present a case of possible transfusion‐transmitted Ehrlichia chaffeensis infection in a heavily transfused cord blood transplant recipient, resulting in severe infection and graft loss. Transfusion‐transmitted, vector‐borne infections in immunocompromised individuals can have severe consequences, and should be considered in hospitalized patients receiving blood products with unexplained fever or sepsis.
Aspergillus infection of the larynx in a solid organ transplant recipient
Authors: Wisniowski‐Yáñez Andrea , Ramírez‐Anguiano Jaqueline , Rosado‐Canto Rodrigo , Valdivia‐Cayoja Adolfo , Pérez‐Gutiérrez Teresa , Cuellar‐Rodriguez Jennifer 
Published: April 2018

AbstractPrimary laryngeal aspergillosis is a rare condition. Only a few cases have been reported in the past years. Most of them have been reported in healthy patients or with a mild immunocompromised state. We report a case of primary laryngeal aspergillosis in a solid organ transplant recipient (SOT), an infection not previously described in this population; we reviewed the published literature in all populations.
A 20‐year experience with nocardiosis in solid organ transplant (SOT) recipients in the Southwestern United States: A single‐center study
Authors: Majeed Aneela , Beatty Norman , Iftikhar Ahmad , Mushtaq Adeela , Fisher Julia , Gaynor Pryce , Kim Jeeyong C. , Marquez Jose L. , Mora Francisco E. , Georgescu Anca , Zangeneh Tirdad 
Published: April 2018

AbstractBackgroundNocardiosis is a life‐threatening opportunistic infection. Solid organ transplant (SOT) recipients are at higher risk (incidence 0.04%‐3.5%) of developing nocardiosis. Rate of nocardiosis in the Southwestern US may be high due to environmental factors.MethodsWe performed a retrospective review study on 54 SOT patients diagnosed with Nocardia between 1997 and 2016 at our center. To explore the association of various risk factors with both the development of disseminated disease and mortality, a series of Fisher's exact tests was used.FindingsIncidence of nocardiosis in SOT patients was 2.65%. Fisher's exact tests revealed no association between development of disseminated disease and the following variables: transplant rejection (P = 1), elevated tacrolimus levels (P = .4), and CMV viremia (P = .06). Also, we did not find any association between mortality and the variables we evaluated: type of transplant, transplant rejection, renal failure, disseminated nocardia, and patient's age. Overall mortality and 1‐year mortality were 17% and 11%.InterpretationBased on our findings, daily 1 DS TMP/SMX prophylaxis did not appear to provide reliable protection against nocardiosis. However, we could not state definitely that TMP/SMX prophylaxis was or wasn't protective because of lack control group. None of the Fisher's exact tests revealed associations between the tested risk factors and either disease dissemination or mortality. This could be due to a true lack of association between the variables in each pair. However, it is also likely that our relatively small sample size limited our power to detect underlying relationships that may be present. Compared with other studies, 1‐year mortality was lower at our institution (11% vs 16%).
Cytomegalovirus infection in living donor liver transplant recipients significantly impacts the early post‐transplant outcome: A single center experience
Authors: Yadav Sanjay Kumar , Saigal Sanjiv , Choudhary Narendra Singh , Saha Sujeet , Sah Jayant Kumar , Saraf Neeraj , Kumar Naveen , Goja Sanjay , Rastogi Amit , Bhangui Prashant , Soin A.S. 
Published: April 2018

AbstractBackgroundCytomegalovirus (CMV) is the most common viral infection in liver transplant recipients that influences the outcomes of liver transplantation. However, its impact on early outcomes following living donor liver transplantation (LDLT) is not fully defined in the Indian subcontinent. This study was done to assess the impact of CMV infection on early post‐transplant outcomes in LDLT recipients.MethodsOut of 272 LDLTs performed from January 2012 to April 2013, 151 recipients underwent CMV viral load analysis in plasma within 90 days post LDLT based on clinical suspicion. Patients with CMV infection (n = 55) were compared with those without CMV infection (n = 96).ResultsThe median time interval of CMV infection from LDLT was 25 days (range 2‐90 days). The mean age of study population was 48.92 years. About 116 (76.8%) of the patients were male. Hepatitis C virus (HCV) (39.1%)‐related chronic liver disease (CLD) was most common indication for liver transplant. No statistically significant difference was observed in etiology of liver disease (P = .38), Chid‐Turcotte‐Pugh (CTP) (P = .41), and Model for End‐stage Liver Disease (MELD) (P = .12) scores between the groups. Patients with CMV infection had significantly higher incidence of acute cellular rejection (16.1% vs 5.4%, P = .02); longer ICU stay (P = .01); and a higher overall 90‐day mortality (24.2% vs 6.7%, P = .001). Bacteremia and fungemia were significantly more common in the CMV infection group.ConclusionCytomegalovirus infection significantly influences the early post LDLT outcomes and contributes to increased overall mortality.
Patient blood management, what does this actually mean for neonates and infants?
Authors: Crighton G. L. , New H. V. , Liley H. G. , Stanworth S. J. 
Published: April 2018

SUMMARYPatient blood management (PBM) refers to an evidence‐based package of care that aims to improve patient outcomes by optimal use of transfusion therapy, including managing anaemia, preventing blood loss and improving anaemia tolerance in surgical and other patients who may need transfusion. In adults, PBM programmes are well established, yet the definition and implementation of PBM in neonates and children lags behind. Neonates and infants are frequently transfused, yet they are often under‐represented in transfusion trials. Adult PBM programmes may not be directly applicable to these populations. We review the literature in neonatal (and applicable paediatric) transfusion medicine and propose specific neonatal PBM definitions and elements.
Evaluation of Amphotericin B Lipid Formulations for Treatment of Severe Coccidioidomycosis
Authors: Sidhu Ritam , Lash David B. , Heidari Arash , Natarajan Piruthiviraj , Johnson Royce H. 
Published: April 2018

ABSTRACT

Patients with severe coccidioidomycosis infections are often treated with either amphotericin B lipid complex (ABLC) or liposomal amphotericin B (L-AmB). Outcome data with these agents in severe coccidioidomycosis cases are currently lacking. The purpose of this study is to evaluate the efficacy and toxicity of ABLC and L-AmB in treating severe coccidioidomycosis. A retrospective pre-post study design was employed. Chart reviews were completed from 1 January 2005 to 31 December 2014 for all patients who received lipid-based amphotericin B. Inclusion criteria included having a follow-up complement fixation (CF) titer or a treatment emergent adverse event (TEAE) prior to follow-up. Patients with meningeal involvement and pregnant patients were excluded. Treatment outcomes were assessed based on documented completion of therapy as well on symptoms, complement fixation titer, and changes to laboratory monitoring parameters. A total of 108 patients were identified, 69 of whom met the inclusion criteria. There were no statistical differences in demographics or disease burden in those that received ABLC and those that received L-AmB, except that those who received L-AmB were more likely to have previously diagnosed chronic kidney disease (
n
L-AmB
= 4, 12.5% vs
n
ABLC
= 0, 0.0%;
P
= 0.042) and to have a lower creatinine clearance at the start of therapy (L-AmB = 79.6 mg/dl versus ABLC = 100.4 mg/dl;
P
= 0.008). Successful treatment was achieved in 27 (73.0%) of ABLC patients and 22 (68.8%) of L-AmB patients (
P
= 0.700). Amphotericin B was discontinued due to documented completion of therapy for 17 (45.9%) ABLC patients and 18 (56.3%) L-AmB patients (
P
= 0.553). Acute kidney injury (AKI) was the documented reason of treatment cessation for 10 (27.0%) ABLC and 1 (3.1%) L-AmB patient (
P
= 0.007). ABLC and L-AmB both appear to be equally efficacious in the treatment of severe coccidioidomycosis. L-AmB may have less renal toxicity than ABLC and may be the preferred agent in baseline renal impairment.
In Vitro
Activity of Ceftazidime-Avibactam against Isolates from Patients in a Phase 3 Clinical Trial for Treatment of Complicated Intra-abdominal Infections
Authors: Stone Gregory G. , Newell Paul , Bradford Patricia A. 
Published: April 2018

ABSTRACT

The increasing prevalence of multidrug-resistant Gram-negative pathogens has generated a requirement for new treatment options. Avibactam, a novel non-β-lactam–β-lactamase inhibitor, restores the activity of ceftazidime against Ambler class A, C, and some class D β-lactamase-producing strains of
Enterobacteriaceae
and
Pseudomonas aeruginosa
. The
in vitro
activities of ceftazidime-avibactam versus comparators were evaluated against 1,440 clinical isolates obtained in a phase 3 clinical trial in patients with complicated intra-abdominal infections (cIAI; ClinicalTrials.gov identifier NCT01499290). Overall,
in vitro
activities were determined for 803
Enterobacteriaceae
, 70
P. aeruginosa
, 304 Gram-positive aerobic, and 255 anaerobic isolates obtained from 1,066 randomized patients at baseline. Susceptibility was determined by broth microdilution. The most commonly isolated Gram-negative, Gram-positive, and anaerobic pathogens were
Escherichia coli
(
n
= 549),
Streptococcus anginosus
(
n
= 130), and
Bacteroides fragilis
(
n
= 96), respectively. Ceftazidime-avibactam was highly active against isolates of
Enterobacteriaceae
, with an overall MIC
90
of 0.25 mg/liter. In contrast, the MIC
90
for ceftazidime alone was 32 mg/liter. The MIC
90
value for ceftazidime-avibactam (4 mg/liter) was one dilution lower than that of ceftazidime alone (8 mg/liter) against isolates of
Pseudomonas aeruginosa
. The ceftazidime-avibactam MIC
90
for 109 ceftazidime-nonsusceptible
Enterobacteriaceae
isolates was 2 mg/liter, and the MIC range for 6 ceftazidime-nonsusceptible
P. aeruginosa
isolates was 8 to 32 mg/liter. The MIC
90
values were within the range of susceptibility for the study drugs permitted per the protocol in the phase 3 study to provide coverage for aerobic Gram-positive and anaerobic pathogens. These findings demonstrate the
in vitro
activity of ceftazidime-avibactam against bacterial pathogens commonly observed in cIAI patients, including ceftazidime-nonsusceptible
Enterobacteriaceae
. (This study has been registered at ClinicalTrials.gov under identifier NCT01499290.)
Impact of Currently Marketed Tampons and Menstrual Cups on Staphylococcus aureus Growth and Toxic Shock Syndrome Toxin 1 Production
In Vitro
Authors: Nonfoux Louis , Chiaruzzi Myriam , Badiou Cédric , Baude Jessica , Tristan Anne , Thioulouse Jean , Muller Daniel , Prigent-Combaret Claire , Lina Gérard 
Published: April 2018

ABSTRACT

Fifteen currently marketed intravaginal protection products (11 types of tampon and 4 types of menstrual cup) were tested by the modified tampon sac method to determine their effect on
Staphylococcus aureus
growth and toxic shock syndrome toxin 1 (TSST-1) production. Most tampons reduced
S. aureus
growth and TSST-1 production, with differences based on brand and composition, and the level of
S. aureus
growth was higher in destructured than in unaltered tampons. We observed higher levels of
S. aureus
growth and toxin production in menstrual cups than in tampons, potentially due to the additional air introduced into the bag by cups, with differences based on cup composition and size.

IMPORTANCE
Menstrual toxic shock syndrome is a rare but severe disease. It occurs in healthy women vaginally colonized by
Staphylococcus aureus
producing toxic shock syndrome toxin 1 using intravaginal protection, such as tampons or menstrual cups. Intravaginal protection induces TSS by the collection of catamenial products, which act as a growth medium for
S. aureus
. Previous studies evaluated the impact of tampon composition on
S. aureus
producing toxic shock syndrome toxin 1, but they are not recent and did not include menstrual cups. This study demonstrates that highly reproducible results for
S. aureus
growth and TSST-1 production can be obtained by using a simple protocol that reproduces the physiological conditions of tampon and cup usage as closely as possible, providing recommendations for tampon or cup use to both manufacturers and consumers. Notably, our results do not show that menstrual cups are safer than tampons and suggest that they require similar precautions.
Poly(3-Hydroxybutyrate) (PHB) Polymerase PhaC1 and PHB Depolymerase PhaZa1 of Ralstonia eutropha Are Phosphorylated
In Vivo
Authors: Juengert Janina R. , Patterson Cameron , Jendrossek Dieter 
Published: April 2018

ABSTRACT

In this study, we screened poly(3-hydroxybutyrate) (PHB) synthase PhaC1 and PHB depolymerase PhaZa1 of
Ralstonia eutropha
for the presence of phosphorylated residues during the PHB accumulation and PHB degradation phases. Thr373 of PHB synthase PhaC1 was phosphorylated during the stationary growth phase but was not modified during the exponential and PHB accumulation phases. Ser35 of PHB depolymerase PhaZa1 was identified in the phosphorylated form during both the exponential and stationary growth phases. Additional phosphosites were identified for both proteins in sample-dependent forms. Site-directed mutagenesis of the codon for Thr373 and other phosphosites of PhaC1 revealed a strong negative impact on PHB synthase activity. Modifications of Thr26 and Ser35 of PhaZa1 reduced the ability of
R. eutropha
to mobilize PHB in the stationary growth phase. Our results show that phosphorylation of PhaC1 and PhaZa1 can be important for the modulation of the activities of PHB synthase and PHB depolymerase.

IMPORTANCE
Poly(3-hydroxybutyrate) (PHB) and related polyhydroxyalkanoates (PHAs) are important intracellular carbon and energy storage compounds in many prokaryotes. The accumulation of PHB or PHAs increases the fitness of cells during periods of starvation and under other stress conditions. The simultaneous presence of PHB synthase (PhaC1) and PHB depolymerase (PhaZa1) on synthesized PHB granules in
Ralstonia eutropha
(alternative designation,
Cupriavidus necator
) was previously shown in several laboratories. These findings imply that the activities of PHB synthase and PHB depolymerase should be regulated to avoid a futile cycle of simultaneous synthesis and degradation of PHB. Here, we addressed this question by identifying the phosphorylation sites on PhaC1 and PhaZa1 and by site-directed mutagenesis of the identified residues. Furthermore, we conducted
in vitro
and
in vivo
analyses of PHB synthase activity and PHB contents.
Draft Genome Sequence of a Highly Resistant Streptococcus pneumoniae Serotype 15A Strain Isolated from Blood
Authors: Arushothy Revathy , Ahmad Norazah , Amran Fairuz , Hashim Rohaidah , Samsuddin Nazirah , Che Azih Che Roslina 
Published: April 2018

ABSTRACT

After the introduction of the pneumococcal conjugate vaccine in Malaysia in recent years, the emergence of nonvaccine serotypes is of concern, particularly the antibiotic-resistant strains, with an increase specifically in serotype 15A. Here, we report the draft genome sequence of
Streptococcus pneumoniae
strain SS40_16, isolated from the blood sample of a 19-month-old female in 2016. SS40_16 is a multidrug-resistant strain with resistance to penicillin (MIC, ≥2 µg/ml), tetracycline, and trimethoprim-sulfamethoxazole. The strain belongs to serotype 15A and sequence type 1591 (ST1591).
Draft Genome Sequences of 20 Salmonella enterica subsp. enterica Serovar Typhimurium Strains Isolated from Swine in Santa Catarina, Brazil
Authors: Seribelli Amanda Aparecida , Frazão Miliane Rodrigues , Gonzales Júlia Cunha , Cao Guojie , Leon Maria Sanchez , Kich Jalusa Deon , Allard Marc William , Falcão Juliana Pfrimer 
Published: April 2018

ABSTRACT

Salmonellosis is a disease with a high incidence worldwide, and
Salmonella enterica
subsp.
enterica
serovar Typhimurium is one of the most clinically important serovars. We report here the draft genome sequences of 20
S.
Typhimurium strains isolated from swine in Santa Catarina, Brazil. These draft genomes will improve our understanding of
S.
Typhimurium in Brazil.
Partial Mitochondrial Genome Sequences of Two Abyssal Sponges (Porifera: Hexactinellida), Bathydorus laniger and Docosaccus maculatus
Authors: Kahn Amanda S. , Geller Jonathan B. 
Published: April 2018

ABSTRACT

We announce the nearly complete mitochondrial genome sequences of two hexactinellid sponges,
Bathydorus laniger
and
Docosaccus maculatus
. A contiguous region of over 15,000 bp was sequenced from each genome. An uncommon structural element was identified as a series of repetitive elements with sequences matching
cob
in the genome of
D. maculatus
.
First Complete Genome Sequence of a Feline Morbillivirus Isolate from Germany
Authors: Sieg Michael , Vahlenkamp Annett , Baums Christoph Georg , Vahlenkamp Thomas Wilhelm 
Published: April 2018

ABSTRACT
The first cell culture isolation and whole-genome sequence of a feline morbillivirus from Germany are described here. Phylogenetic analysis revealed highest similarity to isolates from Japan and a more distant relationship to strains from Italy, Hong Kong, and the United States. Therefore, feline morbilliviruses should be divided into two different genotypes.
Complete Genome Sequence of a Putative New Bacterial Strain, I507, Isolated from the Indian Ocean
Authors: Wang Shu-yan , Wei Jia-qiang , Chen Hao 
Published: April 2018

ABSTRACT
Bacterial strain I507 was isolated from the central Indian Ocean and may be a potential novel species, according to the 16S rRNA gene sequence. Here, we present its complete genome sequence and expect that it will provide researchers with valuable information to further understand its classification and function in the future.
Complete Genome Sequence of Agrobacterium tumefaciens 1D1609
Authors: Cho Shu-Ting , Haryono Mindia , Chang Hsing-Hua , Santos Mary Nia M. , Lai Erh-Min , Kuo Chih-Horng 
Published: April 2018

ABSTRACT

Agrobacterium tumefaciens
1D1609 is a highly virulent strain isolated from a crown gall tumor of alfalfa (
Medicago sativa
L.). Compared to other well-characterized
A. tumefaciens
strains, such as C58 and Ach5, 1D1609 has a distinctive host range. Here, we report its complete genome sequence to facilitate future studies.
Draft Genome Sequences of Five Staphylococcus aureus Strains Isolated from Clinically Healthy Cows in the Russian Federation
Authors: Fursova Ksenia K. , Artem’eva Olga A. , Nikanova Daria A. , Larin Andrey K. , Zinovieva Natalia A. , Brovko Fedor A. 
Published: April 2018

ABSTRACT

We present here the draft genome sequences of five
Staphylococcus aureus
strains isolated from milk samples from clinically healthy cows in the Russian Federation. Four of them were determined to be sequence type 97 (ST-97), and one was determined to be ST-22. All the strains are characterized by their genome possessing genes that code for enterotoxins and cytotoxins.
A World Health Organization Human Hepatitis E Virus Reference Strain Related to Similar Strains Isolated from Rabbits
Authors: Kaiser Marco , Delaune Déborah , Chazouillères Olivier , Blümel Johannes , Roque-Afonso Anne-Marie , Baylis Sally A. 
Published: April 2018

ABSTRACT
We report here the genome sequence of a hepatitis E virus (HEV) strain from a chronically infected immunodeficient patient. Full-length sequence analysis revealed a distinct HEV strain, of a tentative new subgenotype, clustering with viruses from rabbits. It is a World Health Organization reference strain for validation of nucleic acid testing.
Draft Genome Sequence of a Shewanella halifaxensis Strain Isolated from the Intestine of Marine Red Seabream (Pagrus major), Which Includes an Integrative Conjugative Element with Macrolide Resistance Genes
Authors: Sugimoto Yuta , Maruyama Fumito , Suzuki Satoru 
Published: April 2018

ABSTRACT

Shewanella halifaxensis
strain 6JANF4-E-4 was isolated from the intestine of a red seabream (
Pagrus major
). Here, we report the draft genome sequence of this bacterium, which includes an integrative conjugative element of the SXT/R391 family, where the macrolide resistance determinants
mef
(C) and
mph
(G) exist.